Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVETING: Tofacitinib dose reduction in stable UC
NCT03281304Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Nov 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 4 trial of tofacitinib oral solution in ulcerative colitis (UC), sponsored by Pfizer. Started Nov 2017; status: terminated.
02
Drugs
tofacitinib oral solution
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03281304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281304.